Showing 5121-5130 of 8729 results for "".
- TRuE-AD3: Ruxolitinib Cream Safe in Pediatric Atopic Dermatitis Patientshttps://practicaldermatology.com/news/true-ad3-ruxolitinib-cream-safe-pediatric-atopic-dermatitis-patients/2467445/Ruxolitinib applied twice daily did not appear to impact hematologic parameters in any clinically meaningful way, according to a new study. "In two randomized phase 3 studies (TRuE-AD1 and TRuE-AD2) evaluating ruxolitinib (Janus kinase [JAK]1/JAK2 inhibitor) cream in adults and adolescent
- Analysis: Ruxolitinib 1.5% Cream Linked with Repigmentation in Adolescents with Vitiligohttps://practicaldermatology.com/news/phase-3-trials-reveal-enhanced-repigmentation-adolescents-vitiligo/2467443/A new post-hoc analysis indicates significant repigmentation results from the application of 1.5% ruxolitinib cream in patients with nonsegmental vitiligo. The analysis looked at two double-blind, vehicle-controlled studies (the TRuE-V1 and TRuE-V2 phase 3 clinical trials). Patients were
- Study: CBD Cream Shows Promise in Reducing Sun-Induced Skin Injuryhttps://practicaldermatology.com/news/study-cbd-cream-shows-promise-reducing-sun-induced-skin-injury/2467423/New research from the George Washington University School of Medicine and Health Sciences, in collaboration with the Center for Clinical and Cosmetic Research, suggests that cannabidiol (CBD) has potential in preventing skin damage from ultraviolet-A (UVA) radiation. Researchers for the 1
- Taylor Fritz Partners with La Roche-Posay for Sun Safety Campaignhttps://practicaldermatology.com/news/taylor-fritz-partners-la-roche-posay-sun-safety-campaign/2467419/La Roche-Posay has partnered with professional tennis player Taylor Fritz to promote awareness of sun safety practices, according to a news release. Taylor Fritz, currently the highest-ranked American male tennis player, will serve as the sun safety spokesperson for La Roche-Posay to high
- Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeuticshttps://practicaldermatology.com/news/Johnson-johnson-completes-acquisition-yellow-jersey-therapeutics/2467362/Johnson & Johnson has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics, to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody being evaluated for the treatment of atopic dermatitis
- Study: Dupilumab Shows Sustained Benefit for Severe ADhttps://practicaldermatology.com/news/study-dupilumab-shows-sustained-benefit-severe-ad/2467337/New research on the long-term safety and efficacy of dupilumab in adults with moderate to severe atopic dermatitis (AD) indicates that dupilumab was safe and effective in the long-term treatment of the condition. The open-label extension study was conducted over a period of 5 years in 28
- Study: Omega-3 Supplementation Reduces Acne Severityhttps://practicaldermatology.com/news/study-omega-3-supplementation-reduces-acne-severity/2467299/New research suggests there may be potential benefits of omega-3 fatty acids (ω-3 FA) in managing acne severity through dietary intervention and supplementation. Study researchers publishing in the Journal of Cosmetic Dermatology focused their efforts on eicosapentaenoic acid (EP
- AQUA Dermatology Partners With First Coast Mohshttps://practicaldermatology.com/news/aqua-dermatology-partners-first-coast-mohs/2467290/AQUA Dermatology, backed by private-equity firms Gryphon Investors and GTCR, announced it now has 110 locations in the southeastern United States and more than 250 practitioners as a result of a new partnership with Jacksonville, Florida-based First Coast Mohs. First Coast Mohs will conti
- FDA Approves sNDA for Roflumilast Cream, 0.15%, for Mild-to-Moderate ADhttps://practicaldermatology.com/news/fda-approves-snda-roflumilast-cream-015-mild-moderate-ad/2467287/The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild-to-moderate atopic dermatitis (AD) in adult and pediatric patients 6 years of age and older, Arcutis Biotherapeutics, Inc. announc
- Platelet-Rich Plasma Improves Outcomes in Severe ADhttps://practicaldermatology.com/news/platelet-rich-plasma-improves-outcomes-severe-ad/2467268/A new study looking at platelet-rich plasma (PRP) as an adjuvant therapy for adult atopic dermatitis (AD) suggested the treatment was associated with favorable outcomes. The literature search focused on original English-language articles about PRP as a therapeutic method for adult AD. Revi